Form 4: Alector Executive Bolsters Stake with Significant Equity Grants

Alector, Inc.'s President and Head of R&D, Sara Kenkare-Mitra, has acquired 54,725 restricted stock units and 18,250 employee stock options, aligning executive incentives with future company performance.

Summary

• Sara Kenkare-Mitra, President and Head of R&D of Alector, Inc., acquired 54,725 shares of Common Stock through Restricted Stock Units (RSUs) on July 1, 2025.
• These RSUs were acquired at a price of $0.00 per share, indicating a grant of equity compensation.
• The vesting schedule for the RSUs is 50% on December 1, 2025, and 25% quarterly thereafter.
• Additionally, Kenkare-Mitra acquired 18,250 Employee Stock Options on July 1, 2025, with an exercise price of $1.42 per share.
• The vesting schedule for the stock options is one-third on November 1, 2025, and one-twelfth in equal monthly installments thereafter, with full vesting by July 1, 2026.
• Following these transactions, Kenkare-Mitra beneficially owns 566,977 shares of Common Stock and 18,250 Employee Stock Options directly.

Sentiment

Score: 7

Explanation: The document reports equity grants to a key executive, which is a positive sign for aligning management interests with shareholder value and executive retention. It does not, however, provide direct financial performance data or indicate any negative developments.

Positives

• Acquisition of 54,725 Restricted Stock Units (RSUs) at $0.00, representing a direct grant of equity compensation to a key executive.
• Acquisition of 18,250 Employee Stock Options with an exercise price of $1.42, providing potential future upside for the executive.
• Increased beneficial ownership by the President and Head of R&D, Sara Kenkare-Mitra, which enhances alignment of management interests with shareholder value.

Future Outlook

The grants of restricted stock units and stock options with future vesting dates indicate a long-term incentive structure for the executive, aligning their future performance with the company's success and encouraging retention.

Industry Context

Equity grants to key executives like the President and Head of R&D are a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize top talent. This aligns the executive's financial interests with the long-term success of Alector's drug development pipeline, which is crucial given the extended development cycles and inherent risks in the sector.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a standard practice across the biotechnology and pharmaceutical sectors for executive remuneration, comparable to practices at companies like Biogen, Amgen, or Regeneron.
• The vesting schedules, extending over several years, are typical for long-term incentive plans in the industry, designed to retain executives and incentivize sustained performance.
• The grant of options with a specific exercise price and RSUs at a $0.00 price (representing a direct share grant) is a common structure for performance-based or retention-based equity awards in the life sciences industry.

Related Party Transactions

• Acquisition of 54,725 Restricted Stock Units (RSUs) by Sara Kenkare-Mitra, President and Head of R&D, from Alector, Inc.
• Acquisition of 18,250 Employee Stock Options by Sara Kenkare-Mitra, President and Head of R&D, from Alector, Inc.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to equity grants, potentially leading to improved long-term company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives, potentially boosting morale and confidence in the company's future.

Next Steps

• Future vesting events for Restricted Stock Units on December 1, 2025, and quarterly thereafter.
• Future vesting events for Employee Stock Options on November 1, 2025, monthly thereafter, and full vesting by July 1, 2026.

Key Dates

Recommendation

Keywords

Alector, ALEC, SEC Form 4, insider transaction, equity compensation, restricted stock units, RSU, stock options, executive compensation, beneficial ownership, Kenkare-Mitra Sara, biotechnology, pharmaceutical, R&D